Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. May consider 20 mg orally once daily for long-term maintenance.
* **Pathological hypersecretory conditions:** Initiate at 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum recommended daily dose is 120 mg. For IV administration, doses above 80 mg should be administered as a continuous infusion.
## Pediatric Dosing
* **GERD (erosive esophagitis):**
* 1-5 years: 10 mg orally once daily for up to 8 weeks.
* 5-16 years: 20 mg orally once daily for up to 8 weeks.
* Adolescents 16-18 years: Dosing is typically the same as adult dosing (40 mg once daily).
* Dosing for pathological hypersecretory conditions in pediatric patients is not well established and requires specialist consultation.
## Dose Adjustments
* **Hepatic impairment:** Maximum daily oral dose should not exceed 20 mg in patients with severe hepatic impairment. For IV administration, a similar reduction may be necessary.
## Contraindications
* Known hypersensitivity to pantoprazole, other benzimidazole derivatives, or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Rilpivirine:** Pantoprazole can decrease rilpivirine plasma concentrations; coadministration is not recommended.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Monitor methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution is advised when coadministering with drugs primarily metabolized by CYP2C19 (e.g., clopidogrel, cilostazol, voriconazole).
* **Iron supplements, antifungals (ketoconazole, itraconazole), digoxin:** Absorption may be decreased due to decreased gastric acidity.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Consider monitoring magnesium levels in patients on long-term therapy, especially those taking concomitant medications like diuretics or digoxin.
* Monitor for signs of bone fracture risk with long-term use.
* Monitor for signs of vitamin B12 deficiency with prolonged therapy.
## Clinical Pearls
* Pantoprazole is available in both oral (delayed-release tablets and granules for oral suspension) and intravenous formulations.
* Oral pantoprazole should be taken at least 1 hour before a meal.
* For patients unable to swallow whole tablets, the delayed-release granules can be mixed with applesauce, mashed potatoes, or pudding, and should be consumed immediately. Do not chew or crush the granules.
* IV pantoprazole should be administered over at least 15 minutes.
* The efficacy of PPIs for non-erosive reflux disease (GERD symptoms without esophagitis) is less well established but they are often used.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information for complete details, including contraindications, warnings, precautions, adverse reactions, and drug interactions, before use.*
